Asset-generation through our game-changing antibody platform
We are driven by curiosity and innovation to develop a solid portfolio based on asset-generation through our game-changing antibody platform, Abiprot™. Our approach is different: we start with patients and their needs for new medicines. Our goal is to generate novel medicines against any disease-modifying human protein target.
We are committed to finding treatments for severe diseases with large unmet clinical needs such as pain and aggressive metastatic cancer using our unique angle of a targeted functionality antibody approach.